Clinical Observation of Benphthalein Soft Capsule Combined with Edaravone in the Treatment of Cerebral Infarction

It is aimed to observe the application effect of benphthalein soft capsules and edaravone in cerebral infarction match. The thesis is developed with the method that a total of 100 patients with cerebral infarction from January 2019 to January 2020 were selected as the research object, and were randomly divided into two groups. The control group was treated with edaravone, and the experimental group was treated with benphthalein soft capsules and edaravone, and the curative effect was analyzed. It turns out that the total effective rate of the experimental group (94.00%) was higher than that of the control group (76.00%), and there was a significant difference between the two groups (P < 0.05). The scores of neurological deficit in both groups were significantly lower than those before treatment, but the neurological deficit in the experimental group was significantly lower than that in the control group after treatment, with significant difference (P < 0.05). The incidence of adverse reactions was 4.00% in the experimental group and 10.00% in the control group, and there was no significant difference between the two groups (P > 0.05). To draw a conclusion, benphthalein soft capsule combined with edaravone can obviously improve the quality of life of patients with cerebral infarction, which is a method worthy of clinical application.